Envisia genomic classifier for suspected idiopathic pulmonary fibrosis
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage, prior authorization, and medical necessity criteria for the Envisia genomic classifier (Veracyte) for patients with interstitial lung disease suspected of idiopathic pulmonary fibrosis when HRCT is not definitive; applies to Medicare Advantage and commercial products of BCBS Rhode Island.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Coverage Criteria
Covered when ALL of the following are met
Refer to HRCT pattern definitions and threshold scenarios where Envisia is unlikely to provide additional diagnostic value (see background and thresholds).
Envisia should not be used when HRCT already shows a typical UIP pattern, because radiographic criteria alone establish the diagnosis (see HRCT definitions in the medical criteria).
Envisia should not be used when HRCT demonstrates CT features most consistent with a non‑IPF diagnosis, since those imaging features point to alternate causes of interstitial lung disease and the classifier would not alter the diagnostic pathway.
Do not order Envisia when a positive classifier result is unlikely to change clinical management — specifically when the clinician already has > 90% confidence in an IPF diagnosis based on available clinical and imaging data.
Member benefits and eligibility are governed by the member's subscriber agreement or employer agreement. Those plan documents supersede the provisions of this medical policy for coverage determinations.
Providers should contact the provider call center to verify member‑specific coverage and prior authorization requirements before ordering testing.
Some commercial self‑funded groups have a contract exclusion for expanded biomarker or genetic testing related to state mandates. For these members, genetic testing services and certain proprietary laboratory analyses may be excluded from coverage or require specific handling per the employer's contract.
Refer to the member's Benefit Booklet and related Genetic Testing Services or Proprietary Laboratory Analyses policy sections to determine whether the Envisia test is covered, not medically necessary, or excluded for a particular self‑funded group.
Billing and Coding
| 81554 | Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP]) |
Provider Responsibilities and Authorization
Prior Authorization Required
Prior authorization is required for the Envisia Genomic Classifier. The test is medically necessary only when the clinical criteria in this policy are met. Laboratories are not permitted to obtain prior authorization or to act on behalf of the ordering physician during authorization, appeals, or other administrative processes. The ordering physician is solely responsible for completing authorization, filing appeals, and managing related administrative requirements. If a laboratory provides a laboratory service that has not been authorized, the service will be denied and the financial liability will rest with the participating laboratory; such services may not be billed to the member.
- Affected test: Envisia Genomic Classifier
- Ordering physician must complete authorization and appeals
- Unauthorized lab services will be denied and billed to the lab, not the member
Verify Coverage and Prior Authorization
Providers must verify member-specific benefits, eligibility, and prior authorization requirements by calling the BCBSRI provider call center before performing testing. Benefits and eligibility are determined by the member's subscriber agreement or employer agreement and those documents supersede this policy.
- Call the provider call center for member-specific coverage and eligibility
- This policy is informational and not a guarantee of payment
Authorization Process Must Be Completed by Ordering Physician
Ordering physicians must complete the authorization process themselves. Laboratories, their representatives, or third parties may not obtain authorization or participate in the authorization or appeal processes on behalf of the ordering physician. BCBSRI considers any laboratory or third-party involvement in the authorization process a policy violation and may take severe action, up to termination from the BCBSRI provider network.
- Only the ordering physician may submit authorizations and appeals
- Third-party or laboratory-assisted authorizations are prohibited and subject to sanctions
Member Financial Responsibility and Denial Risk
If a provider performs services that are determined to be not medically necessary or are non-covered benefits, the provider may not charge the member unless the member was informed in advance and agreed in writing to pay. Non-covered or not-medically-necessary services may result in provider or member financial responsibility.
- Do not bill members for non-covered or not medically necessary services unless prior written member agreement exists
- Verify coverage to avoid unexpected member financial liability
Benefits and Eligibility Verification
Providers should confirm prior authorization requirements and member-specific eligibility through the BCBSRI provider call center prior to testing to avoid denials and financial liability.
- Contact the provider call center for benefits and eligibility verification
- Ensure prior authorization is obtained before submitting claims
Unauthorized Laboratory Services Denied
Services provided by laboratories that have not been authorized will be denied and the participating laboratory will be financially liable. Such services may not be billed to the member or the ordering provider.
- Unauthorized laboratory services are denied and billed to the lab
- Providers must ensure tests are authorized prior to specimen submission
Background and Test Overview
Envisia is a tissue‑based multianalyte genomic classifier performed on bronchoscopic transbronchial biopsy specimens that analyzes gene‑expression patterns to produce a categorical result (for example, high probability of usual interstitial pneumonia [UIP] versus non‑UIP).
The classifier is intended to inform the diagnostic evaluation of patients with suspected idiopathic pulmonary fibrosis when HRCT is not definitive, potentially reducing the need for surgical lung biopsy by integrating molecular data with clinical and imaging findings.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.